SCHEMBL3471972

SCHEMBL3471972

CN(C)CCN(Cc1ccccc1)C(=O)c1cc(-c2ccc(-c3cccc(S(C)(=O)=O)c3)s2)n(-c2ccccc2Cl)n1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 9/20 0.66
NR1H3 Q13133 9/20 0.66
RXRA P19793 7/20 0.66
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
SLC16A3 O15427 2/20 0.39
SLC16A1 P53985 1/20 0.39
MCTS1 Q9ULC4 1/20 0.39
RORA P35398 1/20 0.38
RORC P51449 1/20 0.38
RORB Q92753 1/20 0.38
LIMK2 P53671 1/20 0.37
CNR1 P21554 1/20 0.36
TP53 P04637 2/20 0.35
HSD17B2 P37059 1/20 0.35
POLB P06746 1/20 0.34
MAPT P10636 2/20 0.34
KDM4E B2RXH2 1/20 0.34
ALDH1A1 P00352 1/20 0.34
LMNA P02545 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15641716 0.92 NR1H2 (0.70) NR1H2NR1H3RXRASLC16A3SLC16A1
SCHEMBL3473243 0.90 NR1H2 (0.71) NR1H2NR1H3RXRASLC16A3SLC16A1
SCHEMBL3472550 0.87 NR1H2 (0.69) NR1H2NR1H3RXRASLC16A3SLC16A1
SCHEMBL3474046 0.87 RXRA (0.69) NR1H2NR1H3RXRAKMT2ASLC16A3
SCHEMBL3474140 0.86 NR1H2 (0.73) NR1H2NR1H3RXRASLC16A3SLC16A1
SCHEMBL3473692 0.86 RXRA (0.77) NR1H2NR1H3RXRASLC16A3SLC16A1
SCHEMBL3472554 0.86 NR1H2 (0.70) NR1H2NR1H3RXRASLC16A3SLC16A1
SCHEMBL15641670 0.85 NR1H2 (0.67) NR1H2NR1H3RXRASLC16A3SLC16A1
SCHEMBL3474304 0.85 NR1H2 (0.71) NR1H2NR1H3RXRASLC16A3SLC16A1
SCHEMBL3474852 0.84 RXRA (0.71) NR1H2NR1H3RXRASLC16A3SLC16A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8703805-B2 Modulators of LXR EXELIXIS PATENT COMPANY LLC (US) 2014-04-22 US claimed
US-8703805-B2 Modulators of LXR EXELIXIS PATENT COMPANY LLC (US) 2014-04-22 US disclosed
US-8703805-B2 Modulators of LXR EXELIXIS PATENT COMPANY LLC (US) 2014-04-22 US disclosed
US-8703805-B2 Modulators of LXR EXELIXIS PATENT COMPANY LLC (US) 2014-04-22 US disclosed
US-20100331295-A1 MODULATORS OF LXR EXELIXIS, INC. (US) 2010-12-30 US disclosed
US-20100331295-A1 MODULATORS OF LXR EXELIXIS, INC. (US) 2010-12-30 US disclosed
US-20100331295-A1 MODULATORS OF LXR EXELIXIS, INC. (US) 2010-12-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100331295-A1 MODULATORS OF LXR NR1H2, NR1H3, NR1H4 NR1H2 1/4885NR1H3 2/4885RXRA 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.